Determinants of response and resistance to cytotoxics

Seminars in Oncology

Volumn 29, Issue 1 SUPPL. 4, 2002, Pages 110-118

  Rosell, Rafael ^a   Monzó, Mariano ^a   Alberola, Vicente ^a   Taron, Miquel ^a   Barnadas, Agustin ^a   Sánchez, Jose Miguel ^a   Manzano, Jose Luis ^a   Sanchez, José Javier ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; EPOTHILONE DERIVATIVE; GEMCITABINE; IRINOTECAN; MOLECULAR MARKER; OXALIPLATIN;

CANCER CHEMOTHERAPY; CLINICAL TRIAL; DNA DETERMINATION; GENETIC RESISTANCE; HUMAN; LUNG NON SMALL CELL CANCER; MULTIDRUG RESISTANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RNA ANALYSIS; SURVIVAL RATE;

EID: 0036118297     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.31532     Document Type: Article

References (32)

1. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line
2. A variant within the DNA repair gene XRCC 3 is associated with the development of melanoma skin cancer
3. Down-regulation of X-linked inhibitor of apoprosis protein induces apoptosis in chemoresistant human ovarian cancer cells
4. An informatics approach identifying markers of chemosensitivity in human cancer cell lines
5. Apoptosis: Implications of basic research for clinical oncology
6. Identification of single nucleotide polymorphisms in human DNA repair genes
7. 105Val polymorphism
8. Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: A case-control study
9. Pharmacogenomic research and serum DNA analysis in the treatment of non-small cell lung cancer (NSCLC)
10. Beta-tubulin mutations in circulating extracellular DNA of non-small-cell lung cancer (NSCLC) patients (pts)
11. Predictive molecular markers in non-small cell lung cancer
12. Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1a1 and association with breast cancer among African Americans
13. UGT1a1 genotyping correlates with toxicity and survival in non-small-cell lung cancer (NSCLC) patients treated with second-line CPT-11/docetaxel
14. TMS1, a novel proapoptotic caspase recruitment domain protein, is a target of methylation-induced gene silencing in human breast cancers
15. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN
16. Caspase-8/ FLICE functions as an executioner caspase in anticancer drug-induced apoptosis
17. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents
18. Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer
19. Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis
20. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy
21. Expression of ERCC1 antisense RNA abrogates gemcitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair
22. Altered ERCC1 expression correlates with response to cisplatin (DDP) + gemcitabine (GEM) in non-small-cell lung cancer (NSCLC) patients (pts)
23. Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer
24. Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIa N2 non-small-cell lung cancer: A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955)
25. Association of chromosome 11 locus D11S12 with histology, stage, and metastases in lung cancer
26. A 1.4-MB high-resolution physical map and contig of chromosome segment 11p15.5 and genes in the LOH11A metastasis suppressor region
27. Allele loss in chromosome segment 11p15.5 predicts survival of patients with stage I lung cancer
28. Thymidylate synthase expression correlates closely with E2F1 expression in colon cancer
29. Down-regulation of thymidylate synthase gene expression after oxaliplatin administration: Implications for the synergistic activity of sequential oxaliplatin/5FU in sensitive and 5FU-resistant cell lines
30. Assessment of XIAP (X-linked inhibitor of apoptosis) as a novel prognostic marker in radically resected non-small-cell lung cancer (NSCLC) patients
31. Altered HOX and WNT7A expression in human lung cancer
32. Single agent gemcitabine (G) and docetaxel (D) in randomized "cross-over" phase II studies in advanced NSCLC